

GEN PROBE INC  
Form 8-K  
June 15, 2006

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 13, 2006**

**Gen-Probe Incorporated**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction of  
Incorporation)

**001-31279**  
(Commission  
File Number)

**33-0044608**  
(I.R.S. Employer  
Identification No.)

**10210 Genetic Center Drive  
San Diego, CA**  
(Address of Principal Executive Offices)

**92121**  
(Zip Code)

**(858) 410-8000**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01 Other Events.

SIGNATURE

---

**Table of Contents**

**Item 8.01 Other Events.**

On June 13, 2006, Gen-Probe Incorporated ( "Gen-Probe" ) entered into a Professional Services Agreement with Gerald D. Laubach, Ph.D. (the "Agreement" ), pursuant to which Dr. Laubach will serve as a Director Emeritus. Dr. Laubach previously served as a Director on Gen-Probe's Board of Directors (the "Board" ) from September 9, 2002 until his retirement from the Board on May 17, 2006. Under the Agreement, Dr. Laubach will also consult with Gen-Probe on matters of mutual interest, including Gen-Probe's programs in the oncology field. Gen-Probe will pay Dr. Laubach \$2,500 per calendar quarter during the term of the Agreement, and a fee of \$3,000 for each meeting Dr. Laubach attends in connection with the Agreement. The Agreement terminates on June 13, 2007, unless otherwise extended by the parties.

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 15, 2006

GEN-PROBE INCORPORATED

By: /s/ R. William Bowen  
R. William Bowen  
Vice President, General Counsel and  
Corporate Secretary